Company / Operating Income per Share
SAB Biotherapeutics, Inc. Operating Income per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$4.62
FY2025
5-year range
-$5.74 / $0.79
FY2021-FY2025
Trend
-11.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-5.74 to $-4.62 over the past 2 years.
Based on SEC 10-K filings.
-4.62 in FY2025.
Improved from $-5.74 to $-4.62 over the past 2 years.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income per share decreased 11.9% year-over-year.
- Peak operating income per share was recorded in FY2021.
- Lowest operating income per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.62 | -11.9% |
| FY2024 | -$4.13 | +28.1% |
| FY2023 | -$5.74 | -1012.6% |
| FY2022 | -$0.52 | -165.2% |
| FY2021 | $0.79 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026